Transaction overview
Aftab Dana, who serves as Executive Vice President, Research and Development at Exelixis, Inc. (NASDAQ: EXEL), sold 47,918 shares of the company’s common stock on February 24, 2026, at a price of $44.50 per share. The proceeds from the sale totaled $2,132,351.
Position after the sale
Following the disposition, Dana directly holds 616,106 shares of Exelixis common stock. That total includes 414,043 shares that are issuable upon vesting of restricted stock units (RSUs) and performance stock units (PSUs) granted on March 31, 2025. In addition to direct ownership, Dana indirectly owns 5,835 shares through participation in the Exelixis, Inc. 401(k) Plan.
Valuation and company health
InvestingPro analysis referenced alongside the transaction indicates Exelixis is trading below its intrinsic value and reports a price-to-earnings ratio of 16.04. The platform also assigns Exelixis an "EXCELLENT" financial health score and places the company’s market value at $11.51 billion.
Recent financial results
Exelixis released fourth-quarter 2025 financial results that showed mixed performance. The company reported earnings per share (EPS) of $0.97, outperforming the consensus forecast of $0.80 by 21.25%. Revenue for the quarter was $598.66 million, falling short of the expected $604.56 million.
Analyst reactions and program developments
In response to the quarterly report, H.C. Wainwright raised its Exelixis price target from $52 to $54 while maintaining a Buy rating, citing the EPS beat and attributing it in part to lower-than-expected tax expenses. Citizens left its Market Outperform rating and $50 price target intact and highlighted optimism around Exelixis’s cancer candidate zanzalintinib. Discussion at the ESMO 2025 meeting was noted as reinforcing interest in the drug’s potential in metastatic colorectal cancer.
Context and implications
The insider sale, the third-party valuation signal, the mixed quarterly results, and the analyst commentary together present a multifaceted view of the company’s near-term profile. The transaction and the financial report each offer different lenses on investor sentiment and the market’s assessment of Exelixis’s operational and development trajectory.
Note: This article presents transaction details and company disclosures as reported.